National Blood Donor Month: Incentivizing Donations and Meeting Supply Needs

Video

Encouraging and incentivizing donations is essential to ensuring supplies of all blood types are met.

A key challenge faced by blood suppliers—such as the American Red Cross—is ensuring supply demands of all blood types are met. Of course, one factor of the solution stems from encouraging individuals to donate blood.

And yet, barriers such as reticence can prevent or discourage one from doing so.

“The number one reason that people give as to why they’ve never donated is that they’ve never been asked to donate,” Rodney Wilson, Senior Biomedical Communications Specialist of American Red Cross, tells HCPLive® in an interview

“Most people don’t even realize this is a daily need,” he continued.

He explained the importance of working through community organizations and leveraging familiarity within communities. In particular, members within the community volunteering with the Red Cross can encouraging participation through direct and personal communication with neighbors.

“We find that the personal ask ultimately makes a big difference,” Wilson said. “When people realize that there is a need and get a specific ask from someone they know, they seem very willing to do it.”

Wilson also discussed the Red Cross’s offering of coronavirus disease 2019 (COVID-19) antibody tests, another strategy that has particularly garnered a degree of interest among potential donors.

Beyond simply informing donors of their prior COVID-19 status, the donation process can benefit those ill with the virus through use of donor convalescent plasma.

Related Videos
Elna Saah, MD: Unraveling the Current Landscape of Sickle Cell Disease | Image Credit: Twitter
Hematopoietic Stem Cell Transplantation Improves Pediatric SCD Outcomes | Image Credit: Scott Graham/Unsplash
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
© 2024 MJH Life Sciences

All rights reserved.